natgillin/translations-raw huggingface dataset:
In repeat-dose toxicity studies boceprevir showed testicular degeneration in rats at systemic exposures lower than those in humans at the recommended human therapeutic dose. 
Istraživanja toksičnosti ponovljenih doza boceprevira pokazala su degeneraciju testisa u štakora pri sistemskoj izloženosti nižoj od izloženosti u ljudi pri preporučenim terapijskim dozama.
Each hard capsule contains 200 mg boceprevir. 
Jedna tvrda kapsula sadrži 200 mg boceprevira.
Chest: being short of breath when lying flat; serious lung infection like pneumonia; sharp chest pains which are worse when breathing; pain behind breast bone which can spread to neck and 
Prsni koš: nedostatak zraka pri ležanju na ravnom; teška infekcija pluća poput upale pluća; oštra bol u prsnom košu koja se pogoršava pri disanju; bol iza prsne kosti koja se može širiti u
Caution should be exercised in patients taking drospirenone-containing medicines with conditions that predispose them to hyperkalaemia or patients taking potassium-sparing diuretics. 
Potreban je oprez u bolesnika koji uzimaju lijekove koji sadrže drospirenon i imaju tegobe zbog kojih postoji predispozicija za razvoj hiperkalijemije kao i u bolesnika koji uzimaju diuretike koji štede kalij.
Victrelis contains lactose 
Victrelis sadrži laktozu
Combination therapy of Victrelis, peginterferon alfa and ribavirin may influence some patients' ability to drive and use machines. 
Liječenje kombinacijom lijeka Victrelis, peginterferona alfa i ribavirina može u nekih bolesnika utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
• have low blood potassium (hypokalaemia) 
• ako imate nisku razinu kalija u krvi (hipokalijemiju).
Victrelis 200 mg hard capsules boceprevir 
Victrelis 200 mg tvrde kapsule boceprevir
• CYP3A4 inducer medicines (such as antibiotic medicine - rifampicin, and anticonvulsant medicines - carbamazepine, phenobarbital, phenytoin) 
• lijekove koji su induktori enzima CYP3A4 (kao što su antibiotici - rifampicin i lijekovi protiv napadaja - karbamazepin, fenobarbital, fenitoin)
All patients in this treatment arm were limited to 32 weeks of Victrelis. 
Svim bolesnicima u ovoj terapijskoj skupini liječenje lijekom Victrelis bilo je ograničeno na 32 tjedna.
† Rates for patients who are previously untreated 
Bolesnici koji prethodno nisu bili liječeni
HBV/HCV co-infected patients are at risk of HBV reactivation, and should therefore be monitored and managed according to current 
Bolesnici istodobno zaraženi HBV-om/HCV-om izloženi su riziku od reaktivacije HBV-a te ih stoga treba pratiti i liječiti sukladno važećim kliničkim smjernicama.
The TW 4 response was a stronger predictor of SVR compared to response to previous treatment and allowed the determination of the subject's on-treatment interferon 
Odgovor u 4. tjednu liječenja bio je jači pretkazatelj SVR nego odgovor na prethodno liječenje i omogućavao je određivanje odgovora ispitanika na interferon tijekom liječenja.
drospirenone AUC ↑ 99% drospirenone Cmax ↑ 57% 
drospirenon AUC ↑ 99% drospirenon Cmax ↑ 57%
Population pharmacokinetic analysis of Victrelis indicated that age had no apparent effect on exposure. 
Populacijska farmakokinetička analiza lijeka Victrelis ukazala je da dob nema vidljivog učinka na izloženost lijeku.
The race distribution of subjects was as follows: 77% White, 19% Black, and 4% others. 
Raspodjela ispitanika po rasama bila je kako slijedi: 77% bijelaca, 19% crnaca i 4% ostalih.
The ovulation suppression activity of oral contraceptives containing lower doses of norethindrone/ethinyl estradiol and of other forms of hormonal contraception during coadministration with Victrelis has not been established. 
Nije utvrđeno djelovanje oralnih kontraceptiva koji sadrže niže doze noretindrona/etinilestradiola i drugih oblika hormonske kontracepcije na supresiju ovulacije tijekom istodobne primjene s lijekom Victrelis.
Patients receiving prednisone and Victrelis should be monitored appropriately. 
Bolesnike koji primaju prednizon i Victrelis treba nadzirati na odgovarajući način.
• Peginterferon alfa-2b + ribavirin for 48 weeks (PR48). 
• Peginterferon alfa-2b + ribavirin tijekom 48 tjedana (PR48).
If the patient has confirmed, detectable HCV-RNA at TW 24; then discontinue three-medicine 
Ako bolesnik ima potvrđenu mjerljivu HCV-RNK u TL 24; tada prekinite trojnu terapiju.
Pack sizes: carton of 84 hard capsules and multipack containing 336 (4 packs of 84) hard capsules. 
Veličine pakiranja: kutija s 84 tvrde kapsule i višestruko pakiranje koje sadrži 336 tvrdih kapsula
Seven percent of subjects receiving the combination of Victrelis with peginterferon alfa-2b and ribavirin had neutrophil counts of < 0.5 x 10 
Sedam posto ispitanika koji su primali kombinaciju lijeka Victrelis s peginterferonom alfa-2b i ribavirinom imalo je < 0,5 x 10
The antiviral activity of boceprevir was evaluated in a biochemical assay for slow binding inhibitors of NS3 protease and in the genotype 1a and 1b HCV replicon system. 
Protuvirusno djelovanje boceprevira ocijenjeno je biokemijskim testom za sporovezujuće inhibitore NS3 proteaze kao i sustavom replikona HCV-a genotipa 1a i 1b.
Neuropathy peripheral*, cognitive disorder, hyperaesthesia, lethargy, loss of consciousness, mental impairment, neuralgia, presyncope 
periferna neuropatija*, kognitivni poremećaj, hiperestezija, letargija, gubitak svijesti, mentalni poremećaj, neuralgija,
Subjects randomized to receive erythropoietin (N=251) 
Ispitanici randomizirani da primaju eritropoetin (N=251)
SVR rates with “missing=failure” approach were 17/80 [21.3%] for PR48, 94/162 [58.0%] for Victrelis-RGT, 
Stope SVR-a uz pristup "nedostaje = nije odgovorio" bile su 17/80 [21,3%] za PR48, 94/162 [58,0%] za Victrelis-RGT, 106/161 [65,8%] za
Boceprevir is an inhibitor of the HCV NS3 protease. 
Boceprevir je inhibitor NS3 proteaze virusa hepatitisa C (HCV).
If the patient has hepatitis C virus ribonucleic acid (HCV-RNA) results greater than or equal to 1,000 IU/mL at TW 8; then discontinue three-medicine regimen. 
Ako bolesnik ima nalaz ribonukleinske kiseline virusa hepatitisa C (HCV-RNK) veći ili jednak 1000 IU/ml u TL 8; tada prekinite trojnu terapiju.
If other HCV-RNA values were available after FW 24, the last available value in the period after FW 24 was used. 
Ako su nakon 24. tjedna praćenja bile dostupne i druge vrijednosti HCV-RNK, korištena je posljednja dostupna vrijednost nakon 24. tjedna praćenja.
Boceprevir has been shown to be a p-glycoprotein (P-gp) and breast cancer resistant protein (BCRP) substrate in vitro. 
Pokazalo se da je boceprevir in vitro supstrat za p-glikoprotein (P-gp) i protein koji uzrokuje rezistenciju raka dojke na lijekove (engl.
Victrelis 800 mg three times daily) 
Victrelis 800 mg triput na dan)
Whether on treatment early viral response and/or IL28B genotype could reliably identify those patients who are unlikely to retrieve significant benefit of boceprevir (higher SVR rates or short course treatment duration) on top of the bitherapy is currently under investigation. 
Još se ispituje mogu li se na temelju ranog virološkog odgovora i/ili genotipa IL28B pouzdano otkriti oni bolesnici koji vjerojatno neće imati značajne koristi od dodavanja boceprevira dvojnoj terapiji (više stope SVR ili kraće trajanje liječenja).
Boceprevir, in combination with peginterferon alfa and ribavirin, was evaluated in a total of 98 patients (64 in the boceprevir arm) co-infected with Human Immunodeficiency Virus (HIV) and HCV genotype 1 who were previously untreated for chronic HCV infection (see section 4.8 and 5.1). 
Boceprevir u kombinaciji s peginterferonom alfa i ribavirinom procijenjen je u ukupno 98 bolesnika (64 ih je primalo boceprevir) koji su istodobno bili zaraženi virusom humane imunodeficijencije (HIV) i HCV-om genotipa 1 i koji prethodno nisu bili liječeni zbog kronične HCV infekcije (vidjeti dijelove 4.8 i 5.1).
In clinical trials, HCV-RNA in plasma was measured with the Roche COBAS Taqman 2.0 assay with a limit of detection of 9.3 IU/mL and a limit of quantification of 25 IU/mL. 
U kliničkim ispitivanjima, HCV-RNK u plazmi određivala se testom Roche COBAS Taqman 2.0, s granicom detekcije od 9,3 IU/ml i granicom kvantifikacije od 25 IU/ml.
Caution should be exercised in patients with conditions that predispose them to hyperkalaemia or patients taking potassiumsparing diuretics (see section 4.4). 
Potreban je oprez u bolesnika koji imaju tegobe zbog kojih postoji predispozicija za razvoj hiperkalijemije ili u bolesnika koji uzimaju diuretike koji štede kalij (vidjeti dio 4.4).
Treatment of overdose with Victrelis should consist of general supportive measures, including monitoring of vital signs, and observation of the patient's clinical status. 
Liječenje predoziranja lijekom Victrelis treba obuhvatiti opće suportivne mjere, uključujući nadzor vitalnih znakova i praćenje
If you are breast-feeding, your doctor will advise you to discontinue breast-feeding or to discontinue Victrelis while breast-feeding. 
Ako dojite, liječnik će Vam savjetovati da prestanete dojiti ili da prekinete uzimati Victrelis dok dojite.
• have another liver problem in addition to hepatitis C infection • have HIV (human immunodeficiency virus) or have ever had any other problems with your 
• ako ste zaraženi virusom HIV-a (virusom humane imunodeficijencije) ili ste nekad imali drugih problema s imunološkim sustavom
If therapy is initiated, a very close monitoring for signs of infections and worsening liver function is warranted. 
Ako se terapija uvede, neophodan je vrlo poman nadzor kako bi se uočili eventualni znakovi infekcija ili
Victrelis must not be used by itself. 
Victrelis se ne smije koristiti kao jedini lijek.
Each capsule has a yellowish-brown, opaque cap with an "MSD" logo imprinted in red ink and offwhite, opaque body with the code "314" imprinted in red ink. 
Kapsula ima žućkasto-smeđu neprozirnu kapicu s logotipom "MSD" otisnutim crvenom tintom i bjelkasto neprozirno tijelo s oznakom "314" otisnutom crvenom tintom.
If a patient misses a dose and it is less than 2 hours before the next dose is due, the missed dose 
Ako bolesnik propusti dozu, a do sljedeće je doze ostalo manje od 2 sata, propuštenu dozu treba
Mean age of subjects randomized was 43.6 years. 
Srednja dob randomiziranih ispitanika bila je 43,6 godina.
No data are available; therefore, the combination of boceprevir with these medicines is not-recommended (see section 4.4). 
Podaci nisu dostupni te se ne preporučuje kombinacija boceprevira s tim lijekovima (vidjeti dio 4.4).
Mean age of subjects randomized was 49.1 years. 
Srednja dob randomiziranih ispitanika bila je 49,1 godina.
In a study comparing the use of ribavirin dose reduction and erythropoesis stimulating agents in the management of treatment-emergent anaemia, the use of erythropoesis stimulating agents was associated with an increased risk of thromboembolic events (see section 5.1). 
U ispitivanju u kojem se uspoređivalo sniženje doze ribavirina u odnosu na primjenu lijekova koji stimuliraju eritropoezu za liječenje anemije koja se javlja pri liječenju, primjena lijekova koji stimuliraju eritropoezu bila je povezana s povećanim rizikom od tromboembolijskih događaja (vidjeti
Plasma trough concentrations of Victrelis were decreased when administered with efavirenz. 
Najniže koncentracije lijeka Victrelis u plazmi snižene su kad se primjenjuje istodobno s efavirenzom.
The addition of boceprevir to peginterferon alfa and ribavirin is associated with an additional decrease in haemoglobin concentrations of approximately 1 g/dL by Treatment Week 8 compared to standard of care (see section 4.8). 
Dodavanje boceprevira peginterferonu alfa i ribavirinu povezano je s dodatnim sniženjem koncentracije hemoglobina od približno 1 g/dl do 8. tjedna liječenja u usporedbi sa standardnim liječenjem (vidjeti dio 4.8).
9/L) was higher in boceprevir-treated patients (29%) than in placebo-treated patients (17%), in combination with peginterferon alfa-2b and ribavirin. 
9/l) bio je veći u skupinama liječenima boceprevirom (29%) nego u bolesnika koji su primali placebo (17%) u kombinaciji s peginterferonom alfa-2b i ribavirinom.
(CYP3A inhibition and/or P-gp 
(inhibicija CYP3A i/ili inhibicija P-gp-a)
In clinical trials, HCV-RNA in plasma was measured with a Roche COBAS Taqman assay with a limit of detection of 9.3 IU/mL and a limit of quantification of 25 IU/mL. 
U kliničkim ispitivanjima HCV-RNK u plazmi određivala se testom Roche COBAS Taqman, s granicom detekcije od 9,3 IU/ml i granicom kvantifikacije od 25 IU/ml.
HIV Nucleoside Reverse Transcriptase Inhibitor (NRTI) 
Nukleozidni inhibitor HIV reverzne transkriptaze (NRTI)
The concomitant use of Victrelis with potent CYP3A4 inducers (rifampicin, carbamazepine, phenobarbital, phenytoin) is not recommended (see section 4.5). 
Ne preporučuje se istodobna primjena lijeka Victrelis sa snažnim induktorima CYP3A4 (rifampicinom, karbamazepinom, fenobarbitalom, fenitoinom) (vidjeti dio 4.5).
All subjects with detectable HCV-RNA in plasma at TW 12 were discontinued from treatment. 
Svi ispitanici s mjerljivom HCV-RNK u plazmi u 12. tjednu isključeni su iz liječenja.
Fifty-seven percent (208/368) of subjects in the Victrelis-RGT arm and 56% (204/366) of subjects in the Victrelis-PR48 arm had undetectable HCV-RNA at TW 8 compared with 17% (60/363) of 
U 57% ispitanika (208/368) u skupini Victrelis-RGT i 56% ispitanika (204/366) u skupini Victrelis-PR48 razine HCV-RNK u 8. tjednu liječenja nisu bile mjerljive, u usporedbi sa 17% ispitanika (60/363) u skupini PR.
Skin and hair: reddening of the skin; bacterial skin infection Stomach and gut: problems digesting food; vomiting blood; vomiting, diarrhoea, and severe right upper corner stomach (abdominal) pain 
Koža i kosa: crvenilo kože; bakterijska infekcija kože Želudac i crijeva: poteškoće pri probavljanju hrane; povraćanje krvi; povraćanje; proljev i jaka bol u gornjem desnom dijelu trbuha (abdomena)
Acute myocardial infarction*, atrial fibrillation*, coronary artery disease*, pericarditis*, pericardial 
akutni infarkt miokarda*, fibrilacija atrija*, bolest koronarnih arterija*, perikarditis*, perikardijalna efuzija
No dose adjustment is required in these patients and in patients with any degree of renal impairment. 
Nije potrebno prilagođavati dozu u tih bolesnika kao ni u bolesnika s bilo kojim stupnjem oštećenja funkcije bubrega.
3 and/or serum albumin < 35 g/L and/or signs of coagulopathy (International Normalized Ratio (INR) > 1.7) at baseline. 
3 i/ili vrijednost albumina u serumu < 35 g/l i/ili znakove koagulopatije (INR (engl.
* The Full Analysis Set (FAS) consisted of all subjects who became anaemic (serum haemoglobin of approximately ≤10 g/dL within the treatment period) and were randomized to using either ribavirin dose reduction or erythropoietin (N=500). 
* Cijeli set analiza (FAS) obuhvaćao je sve ispitanike koji su postali anemični (hemoglobin u serumu približno ≤ 10 g/dl tijekom razdoblja liječenja) te su randomizirani da primaju ili sniženu dozu ribavirina ili eritropoetin (N=500).
The concomitant use of Victrelis with doxazosin and tamsulosin is not recommended (see section 4.5). 
Istodobna primjena lijeka Victrelis s doksazozinom i tamsulozinom se ne preporučuje (vidjeti dio 4.5).
Victrelis contains lactose. 
Victrelis sadrži laktozu.
Patients receiving dabigatran should be monitored appropriately. 
Bolesnike koji uzimaju dabigatran treba odgovarajuće nadzirati.
The degree of added value of Victrelis on top of the bitherapy in C/C patients will depend on the likelihood of achieving SVR with the bitherapy only. 
Stupanj dodane vrijednosti lijeka Victrelis povrh dvojne terapije u bolesnika s genotipom C/C ovisi o vjerojatnosti da postignu SVR samo s dvojnom terapijom.
Among the variants, 91% of V36M, 98% of T54A, 71% of T54S, 78% of V55A, 76% of R155K, 92% of A156S, 96% of I/V170A, 77% of R155K+T54S and 95% of R155K+V36M were undetectable by population sequencing. 
Od svih varijanti, sekvenciranjem populacije nije otkriveno 91% V36M, 98% T54A, 71% T54S, 78% V55A, 76% R155K, 92% A156S, 96% I/V170A, 77% R155K+T54S i 95% R155K+V36M.
Medicines metabolized primarily by CYP3A4/5 may have increased exposure when administered with Victrelis, which could increase or prolong their therapeutic and adverse reactions (see Table 2). 
Može se povećati izloženost lijekovima koji se primarno metaboliziraju putem CYP3A4/5 kad se primjenjuju zajedno s lijekom Victrelis, što može pojačati ili produljiti njihovo terapijsko djelovanje i nuspojave (vidjeti Tablicu 2).
Victrelis is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy (see sections 4.4 and 5.1). 
Victrelis je indiciran za liječenje kronične infekcije virusom hepatitisa C (CHC) genotipa 1 u kombinaciji s peginterferonom alfa i ribavirinom u odraslih bolesnika s kompenziranom bolešću jetre koji prethodno nisu bili liječeni ili nisu odgovorili na prethodnu terapiju (vidjeti dijelove 4.4 i 5.1).
Subjects who enrolled in PROVIDE within 2 weeks after the last dose of PR in the parent study received Victrelis 800 mg three times daily + PR for 44 weeks. 
Ispitanici koji su uključeni u ispitivanje PROVIDE unutar 2 tjedna nakon posljednje doze PR-a u izvornom ispitivanju, primali su Victrelis u dozi od 800 mg triput na dan + PR tijekom 44 tjedna.
The safety profile represented by approximately 1,500 patients for the combination of Victrelis with peginterferon alfa-2b and ribavirin was based on pooled safety data in two clinical trials: one in patients who were previously untreated, and one in patients who had failed prior therapy (see 
Sigurnosni profil kombinacije lijeka Victrelis s peginterferonom alfa-2b i ribavirinom, kojeg predstavlja oko 1500 bolesnika, temelji se na zbirnim podacima o sigurnosti primjene iz dva klinička ispitivanja: jednog u bolesnika koji prethodno nisu bili liječeni i jednog u bolesnika koji nisu odgovorili na prethodnu terapiju (vidjeti dio 5.1).
If there were no such values at and after FW 24, the FW 12 value was used. 
Ako takve vrijednosti nisu postojale u i nakon 24. tjedna praćenja, koristila se vrijednost iz 12. tjedna praćenja.
Refer to the Summary of Product Characteristics for peginterferon alfa and ribavirin for baseline, ontreatment and post-treatment laboratory testing recommendations including haematology, biochemistry (including hepatic function tests), and pregnancy testing. 
Molimo pročitajte Sažetke opisa svojstava lijeka za peginterferon alfa i ribavirin za preporuke o laboratorijskim pretragama na početku, tijekom i nakon liječenja, uključujući hematološke i biokemijske pretrage (uključujući testove jetrene funkcije) te testiranje na trudnoću.
• HIV non-nucleoside reverse transcriptase inhibitor - efavirenz, etravirine 
• nenukleozidni inhibitor reverzne transkriptaze HIV-a - efavirenz, etravirin
Victrelis is partly metabolized by CYP3A4/5. 
Victrelis se dijelom metabolizira putem CYP3A4/5.
The majority of subjects (87%; 85/98) were taking a ritonavir-boosted HIV protease inhibitor (PI) combined with HIV nucleoside reverse transcriptase inhibitors (NRTIs). 
85/98) uzimala neki inhibitor HIV proteaze pojačan ritonavirom u kombinaciji s nukleozidnim inhibitorima HIV reverzne transkriptaze (NRTI).
Boceprevir/medicine derived material was shown to be transferred into the milk of lactating rats. 
Pokazalo se da se boceprevir odnosno materijal koji potječe od lijeka izlučuje u mlijeko štakorica.
Luxembourg/Luxemburg MSD Belgium BVBA/SPRL Tél/Tel: +32(0)27766211 dpoc_belux@merck.com 
Luxembourg/Luxemburg MSD Belgium BVBA/SPRL Tél/Tel: +32(0)27766211 dpoc_belux@merck.com dpoc_czechslovak@merck.com
Subjects who were not able to enrol in this study within 2 weeks received PR for 4 weeks followed by Victrelis 800 mg three times daily + PR for 44 weeks. 
Ispitanici koji nisu mogli biti uključeni u ovo ispitivanje unutar ta 2 tjedna, primali su PR tijekom 4 tjedna, a zatim Victrelis u dozi od 800 mg + PR tijekom 44 tjedna.
Blood: low red blood cell count (anaemia), drop in the number of red blood cells - the signs may include feeling tired, headaches, being short of breath when exercising; low neutrophil count (neutropenia), low number of white blood cells - the signs may include getting more infections than usual - including fever, severe chills, a sore throat or mouth ulcers 
Krv: nizak broj crvenih krvnih stanica (anemija), pad broja crvenih krvnih stanica - znakovi mogu obuhvaćati umor, glavobolje, nedostatak zraka u naporu; nizak broj neutrofila (neutropenija); mali broj bijelih krvnih stanica - znakovi mogu obuhvaćati češće infekcije nego obično - uključujući vrućicu, jaku zimicu, grlobolju ili vrijedove u ustima.
Therefore, female patients of childbearing potential must use an effective contraceptive during treatment and for 4 months after treatment has been concluded. 
Stoga bolesnice reproduktivne dobi moraju primjenjivati djelotvornu kontracepciju tijekom liječenja i 4 mjeseca po njegovu završetku.
Refer to the Summary of Product Characteristics for peginterferon alfa and ribavirin for additional information about how to reduce and/or discontinue the peginterferon alfa and/or ribavirin dose. 
Pročitajte Sažetke opisa svojstava lijeka za peginterferon alfa i ribavirin za dodatne informacije o tome na koji način sniziti dozu i/ili prekinuti primjenu peginterferona alfa i/ili ribavirina.
• tyrosine kinase inhibitors - used as anti-cancer medicines 
• inhibitore tirozin kinaze - za liječenje karcinoma.
A limited number of subjects (n=12) received ≤ 200mg/day of ribavirin for at least 
Mali broj ispitanika (n=12) primao je dozu ribavirina ≤ 200 mg na dan tijekom najmanje 14 dana.
HCV-RNA levels should be monitored at Treatment Weeks 8, 12, and 24, and for other time points as 
Razine HCV-RNK potrebno je kontrolirati u 8., 12. i 24. tjednu liječenja, a u drugim vremenskim točkama prema kliničkoj potrebi.
Dizziness*, headache* 
kašalj*, dispneja*
• have ever had a blood problem such as pancytopenia (a combination of low platelet, red and 
• ako ste nekada imali probleme s krvlju, kao što je pancitopenija (kombinacija premalog broja krvnih pločica, crvenih krvnih stanica i bijelih krvnih stanica)
Achievement of SVR was associated with the subject's response to peginterferon alfa-2b and ribavirin therapy, whether defined by classification of response to previous treatment, or by a decrease in HCVRNA at TW 4 (see Table 7). 
Postizanje SVR povezano je s ispitanikovim odgovorom na liječenje peginterferonom alfa-2b i ribavirinom, definiranim ili prema klasifikaciji odgovora na prethodno liječenje, ili kao smanjenje razine HCV-RNK u 4. tjednu liječenja (vidjeti Tablicu 7).
Increased clinical and laboratory monitoring for HIV and HCV suppression is recommended. 
Preporučuje se pojačan klinički i laboratorijski nadzor radi praćenja supresije HIV-a i HVC-a.
• However, if it is less than 2 hours before your next dose is due, skip the missed dose. 
- Međutim, ako je do sljedeće doze ostalo manje od 2 sata, preskočite propuštenu dozu.
As a conservative measure in view of limitations of the data, in treatment experienced patients early responders, the total treatment duration is recommended to be prolonged to 48 weeks as compared to the tested 36 weeks total treatment duration (tested RGT), with a 12 weeks of peginterferon ribavirin consolidation phase after the end of the tritherapy at week 36. 
Kao konzervativna mjera obzirom na ograničene podatke preporučuje se u već liječenih bolesnika s ranim odgovorom na liječenje produljiti ukupno trajanje liječenja na 48 tjedana, u usporedbi s ukupno 36 tjedana liječenja u kliničkim ispitivanjima (ispitivana RGT), tako da se nakon završetka trojne terapije u 36. tjednu liječenja nastavi s još 12 tjedana konsolidacije peginterferonom i ribavirinom.
The transfusion rate was 4% (10/249) in subjects randomized to receive ribavirin dose reduction and 2% (5/251) in subjects randomized to receive erythropoietin. 
Stopa transfuzije iznosila je 4% (10/249) u ispitanika randomiziranih za snižavanje doze ribavirina te 2% (5/251) u ispitanika randomiziranih za primanje eritropoetina.